title: High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer.
abstract: The heat shock protein 90 (HSP90) is overexpressed and highly associated with poor prognosis in many malignancies. However, the role of HSP90 in gastric cancer has not been thoroughly elucidated. The aim of this study is to investigate the relationship of HSP90 expression with clinicopathological parameters and prognosis in advanced gastric cancer, and estimate the alteration of HSP90 expression after neoadjuvant chemotherapy. HSP90 and matrix metallopeptidase 9 (MMP-9) antigen expression was evaluated by immunohistochemistry in 322 advanced gastric carcinoma samples. The relationships between HSP90 and clinicopathological parameters and prognosis were analyzed. The response of HSP90 level was assessed in chemotherapeutic effect in 54 patients received 1-2 cycles of neoadjuvant chemotherapy. The positive expression of HSP90 was found to be 69.6% in 322 advanced gastric carcinoma samples. HSP90 protein expression was significantly associated with depth invasion (P<0.001), lymph node metastasis (P<0.001) and stage of disease (P<0.001). The positive rates of HSP90 expression were higher in both prominent serosal invasion group (P<0.001) and lymph node metastasis group (P<0.001). Moreover, HSP90 was significantly correlated with MMP-9 among 322 gastric cancer tissues (P<0.001). In univariate and multivariate analyses, HSP90 was an independent prognostic factor for both recurrence-free survival (RFS) and overall survival (OS). These results suggested that HSP90 may play an important role on tumor invasion, metastasis and prognosis, and might act as a promising target for prognostic prediction.
authors: Department of Abdominal Surgery, Affiliated Oncologic Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China.
authors: Jiahong
authors: J
authors: Wang
authors: Shuzhong
authors: S
authors: Cui
authors: Xiangliang
authors: X
authors: Zhang
authors: Yinbing
authors: Y
authors: Wu
authors: Hongsheng
authors: H
authors: Tang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; C112969:HSP90AA1 protein, human; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9
references: Lancet. 2010 Aug 28;376(9742):687-97
references: 20728210
references: Nat Rev Cancer. 2005 Oct;5(10):761-72
references: 16175177
references: Trends Biochem Sci. 2006 Mar;31(3):164-72
references: 16483782
references: BMC Cancer. 2011 Aug 02;11:329
references: 21810227
references: Gut. 2010 Nov;59(11):1501-10
references: 20947885
references: Cancer Res. 2007 Apr 1;67(7):2932-7
references: 17409397
references: Int J Cancer. 2011 Aug 15;129(4):887-95
references: 20957628
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: J Clin Oncol. 2006 May 10;24(14):2137-50
references: 16682732
references: Semin Oncol. 2003 Oct;30(5):709-16
references: 14571418
references: Ann Surg Oncol. 2010 Jun;17(6):1471-4
references: 20180029
references: Cancer Res. 2010 Sep 1;70(17):6978-87
references: 20699364
references: J Clin Invest. 2012 Jun;122(6):2165-75
references: 22585575
references: Gut. 2009 Jul;58(7):1000-9
references: 19520890
references: Histopathology. 2010 May;56(6):694-701
references: 20546334
references: PLoS One. 2008 Mar 05;3(3):e0001722
references: 18320023
references: Cancer Res. 2007 Jan 15;67(2):616-25
references: 17234771
references: J Clin Oncol. 2000 Mar;18(5):1135-49
references: 10694567
references: Mol Cancer Ther. 2007 Mar;6(3):1123-32
references: 17363505
references: Mol Cancer Ther. 2004 Aug;3(8):1021-30
references: 15299085
references: Cancer Sci. 2011 Jul;102(7):1388-95
references: 21453385
references: Curr Med Chem. 2011;18(27):4250-64
references: 21838681
references: Cancer Lett. 2013 May 28;332(2):275-85
references: 21078542
references: N Engl J Med. 2006 Jul 6;355(1):11-20
references: 16822992
references: J Clin Oncol. 2008 Mar 20;26(9):1435-42
references: 18349393